Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting-Reference-Cited by-同舟云学术

Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting

Published:2021-01-27 Issue:4 Volume:60 Page:521-527
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Ringgaard Petersen Thomas¹²,Panou Vasiliki¹³,Meristoudis Christos⁴,Weinreich Ulla Møller¹⁵^ORCID,Røe Oluf Dimitri⁵⁶⁷⁸^ORCID

Affiliation:

1. Department of Respiratory Disease, Aalborg University Hospital, Aalborg, Denmark

2. Department of Oncology, Regional Hospital West Jutland, Herning, Danmark

3. Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark

4. Department of Pathology, Aalborg University Hospital, Aalborg, Denmark

5. The Clinical Institute, Aalborg University, Aalborg, Denmark

6. Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark

7. Department of Oncology, Levanger Hospital, Nord-Trøndelag Health Trust, Levanger, Norway

8. Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2021.1876246

Reference30 articles.

1. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic

2. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

3. Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data

4. Tantibanchachai C. FDA approves drug combination for treating mesothelioma | FDA [cited 2021 Jan 8]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-drug-combination-treating-mesothelioma. 2020.

5. Experimental Production of Mesothelial Tumours of the Pleura by Implantation of Dusts in Laboratory Animals

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BAP1, Wilms’ tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma;Journal of Cancer Research and Clinical Oncology;2024-01-27

2. Pleural Fluid-to-Blood BNP Ratio May Contribute to Prognosis in Malignant Pleural Mesothelioma;Clinics and Practice;2023-09-13

3. Predicting survival for patients with mesothelioma: development of the PLACE prognostic model;BMC Cancer;2023-07-26

4. Prognostic significance of inflammation-related and electrolyte laboratory variables in patients with malignant pleural mesothelioma;Frontiers in Medicine;2023-04-05

5. Intratumor microbiota as a novel potential prognostic indicator in mesothelioma;Frontiers in Immunology;2023-03-14